Modeling studies of screening for BRCA1/2, Lynch syndrome, familial hypercholesterolemia, and hereditary hemochromatosis have demonstrated that population genomic screening can be cost-effective.43,44,45 Our data indicate that limiting genomic screening to these conditions, as some programs have, however, would only identify a minority of the 1 in 30 participants in this program with a potentially actionable result. The gene discussed is BRCA1; the disease is Lynch syndrome.